drugset / Trial / NCT05183204
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Phase 2
Suspended
33 enrolled
Weill Medical College of Cornell University
Kazia Therapeutics Limited · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is for patients with newly diagnosed glioblastoma, as well as patients who have recurring glioblastoma. Subjects will be given daily paxalisib and metformin while also maintaining a ketogenic diet. The purpose of this study is to assess the safety of Paxalisib while maintaining a ketogenic diet (a high fat, low carbohydrate diet) and Metformin (a drug approved by the Food and Drug Administration to treat type 2 diabetes), and to see what effects it has on glioblastoma.
Timeline
- Start
- 2022-02-14
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 850 mg | — |
| Subject | Paxalisib | Small molecule | 60 mg | — |